Tirzepatide

Also known as: Mounjaro (type 2 diabetes), Zepbound (weight management) — these are approved prescription medicines, not sold here

What is it?
Tirzepatide is an appetite-regulating compound that activates two gut hormone receptors (GLP- 1 and GIP) at the same time. This dual action produces greater weight loss and blood sugar improvements than single-target compounds. The version sold here is a research reference, not the approved medicine.

Key Benefits (from research)

• Largest pharmacological weight loss on record – SURMOUNT-1 showed up to 20.9% average weight reduction at the highest dose; 57% of participants lost 20% or more.
• Near-eliminates diabetes progression – A 3-year analysis in prediabetic participants showed a 94% reduction in the rate of progressing to type 2 diabetes.
• Superior blood sugar control — In a head-to-head trial versus semaglutide, tirzepatide reduced HbA1c more at all doses tested.
• Treats sleep apnoea – SURMOUNT-OSA showed a significant reduction in breathing interruptions during sleep — the first approved medicine to demonstrate this effect.
• Improves body composition quality – A sub-study found reductions in fat deposited within muscle tissue beyond what weight loss alone would predict.
• Cardiovascular safety confirmed – SURPASS-CVOT confirmed tirzepatide’s cardiovascular safety and showed reductions in major cardiovascular events versus a comparator drug.

Quick Q&A

What is Tirzepatide used for in research?
It is studied for its dual-receptor effects on weight loss, blood sugar, cardiovascular risk, sleep apnoea, and body composition.

Is it approved for people?
Yes – as Mounjaro and Zepbound by prescription in the UK and US. The compound sold here is
a research reference only, not the approved medicine.

Important Notice
Sold for laboratory research only. Not for human use. Must be 18+.

More information
Tirzepatide is a novel dual agonist of the GIP and GLP-1 receptors. Its dual mechanism of action represents a significant advance in metabolic peptide research, offering greater glycaemic and weight reduction effects than single GLP-1 agonists in preclinical models. One of the most actively researched metabolic peptides. For laboratory research use only.